Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

Episode 25: RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD with Dr. Mark Gillies
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
5-Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS
John W. Kitchens, MD
Annual Meeting Talks
2025

Category: AMD-Neovascular

See more